AU2019251124B2 - Combination therapy for cancers with BRAF mutation - Google Patents

Combination therapy for cancers with BRAF mutation

Info

Publication number
AU2019251124B2
AU2019251124B2 AU2019251124A AU2019251124A AU2019251124B2 AU 2019251124 B2 AU2019251124 B2 AU 2019251124B2 AU 2019251124 A AU2019251124 A AU 2019251124A AU 2019251124 A AU2019251124 A AU 2019251124A AU 2019251124 B2 AU2019251124 B2 AU 2019251124B2
Authority
AU
Australia
Prior art keywords
salt
palbociclib
cobimetinib
cancer
osimertinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019251124A
Other languages
English (en)
Other versions
AU2019251124A1 (en
Inventor
Yiyou Chen
Chun Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cothera Bioscience Guangzhou Co Ltd
Original Assignee
Cothera Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cothera Bioscience Inc filed Critical Cothera Bioscience Inc
Publication of AU2019251124A1 publication Critical patent/AU2019251124A1/en
Application granted granted Critical
Publication of AU2019251124B2 publication Critical patent/AU2019251124B2/en
Assigned to Cothera Bioscience (Guangzhou) Co., Ltd. reassignment Cothera Bioscience (Guangzhou) Co., Ltd. Request for Assignment Assignors: Cothera Bioscience, Inc.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2019251124A 2018-04-08 2019-04-08 Combination therapy for cancers with BRAF mutation Active AU2019251124B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPCT/CN2018/082191 2018-04-08
PCT/CN2018/082191 WO2019195959A1 (en) 2018-04-08 2018-04-08 Combination therapy for cancers with braf mutation
PCT/CN2019/081674 WO2019196764A1 (en) 2018-04-08 2019-04-08 Combination therapy for cancers with braf mutation

Publications (2)

Publication Number Publication Date
AU2019251124A1 AU2019251124A1 (en) 2020-10-22
AU2019251124B2 true AU2019251124B2 (en) 2026-01-08

Family

ID=68163067

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019251124A Active AU2019251124B2 (en) 2018-04-08 2019-04-08 Combination therapy for cancers with BRAF mutation

Country Status (6)

Country Link
US (2) US11753476B2 (https=)
EP (1) EP3773719A4 (https=)
JP (1) JP2021520406A (https=)
CN (2) CN112566660B (https=)
AU (1) AU2019251124B2 (https=)
WO (2) WO2019195959A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3109605A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CA3142351A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
AU2020363101A1 (en) * 2019-10-09 2022-05-05 Cothera Bioscience, Inc. Combination therapy for cancers with KRAS mutation
WO2021081554A1 (en) * 2019-10-22 2021-04-29 Chemistryrx Methods for treating congenital epidermal hyperplasia
CA3205726A1 (en) * 2021-01-25 2022-07-28 Alfredo C. Castro Combination of a 3-(imidazol-4-yl)-4-(amino)-benzenesulfonamide tead inhibitor with an egfr inhibitor and/or mek inhibitor for use in the treatment of lung cancer
JP2024505680A (ja) * 2021-02-05 2024-02-07 ベラステム・インコーポレーテッド 異常な細胞成長を処置するための併用療法
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
CN115944625A (zh) * 2022-09-05 2023-04-11 湖南灵康医疗科技有限公司 一种黑色素瘤治疗药物组合物及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022724A1 (en) * 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Combination anti - cancer therapy
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors
WO2013060872A1 (en) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976790A (en) 1992-03-04 1999-11-02 The Regents Of The University Of California Comparative Genomic Hybridization (CGH)
PT699237E (pt) 1994-03-17 2003-07-31 Merck Patent Gmbh Fvs de cadeia anti-egfr e anticorpos anti-egfr
KR100737090B1 (ko) 2000-02-15 2007-07-06 아스텔라스세이야쿠 가부시키가이샤 축합 이미다졸륨 유도체
US7132511B2 (en) 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
CA2450285C (en) 2001-06-13 2016-08-02 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (egfr)
MXPA05011078A (es) 2003-04-15 2006-01-24 Astellas Pharma Inc Bromuro y sus cristales.
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
DE10355904A1 (de) 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
WO2005094830A1 (en) 2004-03-30 2005-10-13 Pfizer Products Inc. Combinations of signal transduction inhibitors
US20090253770A1 (en) 2004-05-18 2009-10-08 Kurume University Target gene mimitin of myc
JP2008514635A (ja) 2004-09-27 2008-05-08 コーザン バイオサイエンシス インコーポレイテッド 特異的キナーゼ阻害剤
DK1951759T3 (da) 2005-11-12 2010-05-10 Lilly Co Eli Anti-EGFR-antistoffer
JP4806776B2 (ja) 2006-01-27 2011-11-02 国立大学法人 千葉大学 ｃ−ｍｙｃ遺伝子転写抑制因子ＦＩＲのスプライシングバリアント又はイントロン２内の４塩基繰り返し配列による癌検出方法
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
US20100249413A1 (en) 2006-08-25 2010-09-30 Makoto Murai Stabilized pharmaceutical composition
JP5103604B2 (ja) 2006-10-31 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての２−アミノチアゾール−４−カルボン酸アミド
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
EP2225235B1 (en) 2007-10-29 2017-09-06 Merck Sharp & Dohme Corp. Thiazole carboxamide derivatives and their use to treat cancer
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
WO2009146034A2 (en) 2008-03-31 2009-12-03 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
ES2522346T3 (es) 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
WO2010056931A1 (en) 2008-11-14 2010-05-20 Intelligent Oncotherapeutics, Inc. Methods for identification of tumor phenotype and treatment
US8710068B2 (en) 2009-01-19 2014-04-29 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
ES2576061T3 (es) * 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
EP2558092B1 (en) 2010-04-13 2018-06-27 Novartis AG Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer
JP2014156400A (ja) 2011-05-24 2014-08-28 Astellas Pharma Inc 腫瘍の画像診断用標識誘導体
US20140228423A1 (en) 2011-06-01 2014-08-14 Baylor College Of Medicine Biomarkers and therapy for cancer
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
EP2780354A4 (en) 2011-11-16 2015-06-24 Oncomed Pharm Inc HUMAN NOTCH RECEPTOR MUTATIONS AND THEIR USE
US9662329B2 (en) 2012-03-26 2017-05-30 University of Pittsburgh—of the Commonwealth System of Higher Education Use of survivin antagonists in polyomavirus-related disease
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
US20160024591A1 (en) 2013-03-14 2016-01-28 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
MX2015010854A (es) 2013-03-14 2016-07-20 Genentech Inc Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
SG11201507427QA (en) 2013-03-15 2015-10-29 Genentech Inc Compositions and methods for diagnosis and treatment of hepatic cancers
MA38522A1 (fr) 2013-03-21 2017-10-31 Novartis Ag Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur.
US9314460B1 (en) 2013-04-09 2016-04-19 Stc.Unm Method for cancer cell reprogramming
KR101514877B1 (ko) 2013-05-06 2015-04-24 조선대학교산학협력단 ＡＰＥ/Ｒｅｆ -1 및 ＪＡＧ1/Ｎｏｔｃｈ의 대장암 진단용 마커로서의 용도
US20170080093A1 (en) 2013-10-22 2017-03-23 Tyme, Inc. Tyrosine Derivatives And Compositions Comprising Them
WO2015095840A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of cdk and erk inhibitors
US10668055B2 (en) * 2013-12-20 2020-06-02 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of ERK and RAF inhibitors
HUE055747T2 (hu) 2014-04-04 2021-12-28 Astrazeneca Ab EGFR-gátló és MEK-gátló kombinációja NRAS-mutált rák kezelésében történõ alkalmazásra
ES2823756T3 (es) 2014-04-16 2021-05-10 Signal Pharm Llc Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR
EP3392348A3 (en) 2014-06-16 2018-11-21 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
US9814714B2 (en) 2015-05-22 2017-11-14 Plexxikon Inc. Kinase modulation, and indications therefor
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
IL256242B2 (en) 2015-06-22 2024-09-01 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170027951A1 (en) * 2015-07-27 2017-02-02 Southern Research Institute Methods and compositions to treat cancers involving egfr
EP3340990B1 (en) 2015-08-28 2019-09-25 Novartis AG Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US11499972B2 (en) 2015-09-15 2022-11-15 Swedish Health Services Methods and panels of compounds for characterization of glioblastoma multiforme tumors and cancer stem cells thereof
WO2017070475A1 (en) 2015-10-22 2017-04-27 Merrimack Pharmaceuticals, Inc. Methods of treating cancer by administering a mek inhibitor and a combination of anti-egfr antibodies
AU2017205478A1 (en) 2016-01-07 2018-06-28 Swadesh K. Das A method of modulating survival and stemness of cancer stem cells by MDA-9/Syntenin (SDCBP)
WO2017143237A1 (en) 2016-02-17 2017-08-24 Acetylon Pharmaceuticals, Inc. Increasing expression of interferon regulated genes with combinatons of histone deacetylase inhibitors and immunomodulatory drugs
CN108289885B (zh) 2016-09-23 2020-10-20 江苏恒瑞医药股份有限公司 酪氨酸激酶抑制剂在制备治疗癌症药物中的用途
WO2018127786A1 (en) 2017-01-06 2018-07-12 Oslo Universitetssykehus Hf Compositions and methods for determining a treatment course of action
CN106822905B (zh) 2017-03-08 2019-05-17 暨南大学 含Survivin抑制剂和IRE1抑制剂的药物及用途
US12571049B2 (en) 2018-03-21 2026-03-10 Dana-Farber Cancer Institute, Inc. Therapeutic treatment of select diffuse large B cell lymphomas exhibiting distinct pathogenic mechanisms and outcomes
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
CA3109605A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
WO2020034061A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co., Ltd. Biomarkers for cancer therapy
WO2020097901A1 (en) 2018-11-16 2020-05-22 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012022724A1 (en) * 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Combination anti - cancer therapy
WO2012095505A1 (en) * 2011-01-12 2012-07-19 Boehringer Ingelheim International Gmbh Anticancer therapy with dual aurora kinase / mek inhibitors
WO2013060872A1 (en) * 2011-10-27 2013-05-02 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2018218633A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2018223022A1 (en) * 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
E. K. ZIEMKE ET AL: "Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6", CLIN CANCER RES, vol. 22, no. 2, 2016-01-15, pages 405 - 414, DOI: 10.1158/1078-0432.CCR-15-0829 *
Martin, CA et al., "Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance", Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220 *
MISALE S ET AL: "Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer", SCI TRANSL MED, vol. 6, no. 224, 2014-02-19, DOI:10.1126/SCITRANSLMED.3007947 *
PEK M ET AL: "Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer", ONCOGENE, vol. 36, no. 35, 2017-05-01, pages 4975 - 4986, DOI: 10.1038/ONC.2017.120 *
TROIANI TERESA ET AL: "Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition", 2014, DOI: 10.1158/1078-0432.CCR-13-2181 *

Also Published As

Publication number Publication date
WO2019195959A1 (en) 2019-10-17
EP3773719A1 (en) 2021-02-17
CN112566660B (zh) 2025-10-21
CN112566660A (zh) 2021-03-26
AU2019251124A1 (en) 2020-10-22
JP2021520406A (ja) 2021-08-19
EP3773719A4 (en) 2022-03-02
CN121313846A (zh) 2026-01-13
WO2019196764A1 (en) 2019-10-17
US20240059778A1 (en) 2024-02-22
US11753476B2 (en) 2023-09-12
US20210179718A1 (en) 2021-06-17

Similar Documents

Publication Publication Date Title
AU2019251124B2 (en) Combination therapy for cancers with BRAF mutation
US12048698B2 (en) Treatment of HER2 positive cancers
EP2882440B1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
US20120308562A1 (en) Methods of treating mesothelioma with a pi3k inhibitor compound
JP2023553534A (ja) 癌の処置のための併用療法
JP2023553533A (ja) 癌の処置のための併用療法
US20240058339A1 (en) Combination therapy for cancers with kras mutation
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
US20230310436A1 (en) Combination therapy for cancers with kras mutation
HK40018197A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
HK1204976B (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor